Skip over main navigation
  • Log in
  • Basket: (0 items)
Neuroblastoma Australia

Charity Shop Donate
  • Twitter
Menu
  • About Neuroblastoma
    • What is neuroblastoma?
    • Family stories
    • Neuroblastoma Fact Sheet
    • Resources
  • Family Support
    • Latest Health Advisory
    • Newly diagnosed
      • Key statistics
      • Causes & risks
      • Detection, diagnosis & staging
    • On treatment
      • Treatments & side effects
      • Clinical trials
      • Hospital tips
      • Life outside of hospital
      • Related Support Services
    • Post treatment
      • After treatment
      • Late effects
      • Relapse
    • Connecting with others
      • Family support group
      • Bereavement Support
      • Free family activities
    • Apply for an activity pack
  • About Us
    • Our purpose
    • Our story
    • Our people
      • Our Board
      • Our Scientific Advisory Board
      • Our Neuroblastoma Australia Team
    • Our supporters
    • Our finances
    • News
    • Contact us
  • Our Impact
    • Why fund research?
    • Our research projects
      • Current projects
      • Past projects
      • Grant recipients
    • Key research areas
    • Grant applications
  • Fundraise
    • Fundraise for us
    • Fundraising ideas
    • Support our fundraisers
      • All our fundraisers
      • Run2Cure Local
      • #44kmfor44kids
      • 2 Many 2 Young
    • Corporate fundraising
      • Workplace giving
      • Move2Cure
  • Events
    • Our neuroblastoma events
    • Other events
    • Past events
    • Conferences
    • Volunteer
  • Donate
    • Donate today
    • Give monthly
    • Support our appeals
    • In Memory of
    • Leave a gift in your will
  • Admin
    • Log in
  • Basket: (0 items)
  • Key research areas
  1. Our Impact
  2. Key research areas

Key research areas

What’s New in Neuroblastoma Research?

Important research into neuroblastoma is being done right now in many university hospitals, medical centers, and other research institutions around the world. Each year, scientists find out more about what causes the disease and how to improve treatment. 

Researchers are trialling new ways to diagnose and treat different types of cancer. Your child may be invited to be part of a clinical trial to test new ways of treating neuroblastoma - find out more about clinical trials here.

Genetics of neuroblastomas

Researchers now have better tests to look for changes in the genes of neuroblastoma cells. Researchers might know that a change has happened on a certain chromosome (a strand of DNA inside the cell, which contains its genes), but they still need to know more about that gene or what part of a gene has been affected. There are a few different ways that genes change in neuroblastoma:

  • Sometimes there are extra copies of the same gene (called amplification) on a chromosome.
  • Sometimes a chromosome can have missing pieces of DNA (called deletions) or extra pieces of DNA (called gains or additions), which can affect which genes the chromosome has.

Understanding the gene changes in neuroblastoma helps researchers understand which neuroblastomas are likely to be cured with less intense treatment, and which will need more aggressive treatment. More aggressive neuroblastoma tumors are often called high-risk neuroblastomas, while tumors that tend to be easier to treat are called low- or intermediate-risk neuroblastomas. Some of these gene changes are being used now to help cancer care teams determine a child's neuroblastoma stage and risk group. Other gene changes might help researchers find new treatments that work on certain types of neuroblastoma cells.

Here are some specific DNA and gene changes currently being studied:

  • DNA changes on the short arm of chromosome 6 (6p22) are more likely to be seen in neuroblastomas that grow more aggressively.
  • Neuroblastoma cells in older children are more likely to have changes in the ATRX tumor suppressor gene. Tumors with this gene change tend to grow more slowly, but they are also harder to cure. This may help explain why older children tend to have high-risk neuroblastoma while younger children tend to have low- or intermediate-risk neuroblastoma and do better.
  • Changes in or having more than one copy (amplification) of the ALK and MYCN genes are features used to help decide a child's risk group. Some drugs might work well against neuroblastomas with ALK gene changes. Some scientists also are studying how ALK gene changes might be related to extra copies of the MYCN gene in neuroblastoma cells.

Treatment

Survival rates for neuroblastoma have gotten better as doctors have found ways to improve on current treatments, but survival rates for children with high-risk neuroblastoma are not as good as they are for children with low- or intermediate-risk disease. Most research studies about high-risk neuroblastoma (more aggressive and hard to treat tumors) focus on finding the best combinations of chemotherapy drugs, stem cell transplant regimens, immunotherapies and other new treatments to try to cure more children. Current studies of low- and intermediate-risk neuroblastoma are trying to figure out if children can get less treatment and still do as well.


Chemotherapy

The search continues for the best combinations of chemotherapy drugs to treat neuroblastoma.

Several chemotherapy drugs that are already used to treat other cancers, such as topotecan, irinotecan, and temozolomide, are now being studied in combination with other kinds of therapies for use against high-risk neuroblastoma or neuroblastoma that has come back.

Other studies are looking to see if children with low- or intermediate-risk neuroblastoma can be treated with less (or even no) chemotherapy. The goal is to still have the same good results, but with fewer side effects from treatment.


Stem cell transplants

Doctors are also trying to improve the success rate for children with aggressive neuroblastoma with high-dose chemotherapy and stem cell transplants, using different combinations of chemotherapy, radiation therapy, retinoids, and other treatments. A recent clinical trial looked at whether giving two stem cell transplants to children with high-risk neuroblastoma works better than giving just one stem cell transplant. The long-term improvement in survival for children who received two transplants is not yet clear, but early results show that two stem cell transplants, followed by certain kinds of immunotherapy works better than one stem cell transplant . Other studies are looking to see if using stem cells donated from another person (an allogeneic stem cell transplant) might help some children with hard-to-treat tumors. More research will be done to confirm these results. If you have questions about this, talk with your doctor.


Retinoids

Retinoids such as 13-cis-retinoic acid (isotretinoin) have reduced the risk of recurrence after treatment in children with high-risk neuroblastoma, especially when they are given with certain immunotherapy treatments. Giving 13-cis-retinoic acid in combination with different types of chemotherapy drugs, immunotherapies called monoclonal antibodies, and targeted drugs is being studied in a number of clinical trials to help determine the combinations that might work the best.
Targeted drugs

Knowing what makes neuroblastoma cells different from normal cells could lead to new approaches to treating this disease. Newer drugs that target neuroblastoma cells more specifically than standard chemo drugs are now being studied in clinical trials. For example, doctors are now studying medicines that target the pathways inside neuroblastoma cells that help them grow, such as crizotinib (Xalkori) for the ALK pathway and alisertib (MLN8237) for the aurora A pathway.

Crizotinib is a drug that targets cells with changes in the ALK gene. Up to 15% of neuroblastomas have changes in this gene. In an early study, crizotinib was found to cause some neuroblastomas to shrink, although it’s not clear how long this might last, or if giving this drug with certain chemotherapy drugs might work better. Other drugs that target cells with ALK changes are being developed. Some of these are approved for treating other cancers and are being studied to see if they work in neuroblastoma.

Some other drugs that work differently from standard chemo drugs are being studied in clinical trials against neuroblastoma as well. Examples include bortezomib, vorinostat,, temsirolimus, bevacizumab, nifurtimox, and DMFO.

Immunotherapy

Immunotherapy is the use of medicines to help a patient’s own immune system fight cancer. A few different kinds of immunotherapy are being used in neuroblastoma.

Anti-GD2 monoclonal antibodies

The monoclonal antibody dinutuximab (Unituxin®), which targets GD2 on neuroblastoma cells, is now used routinely for children with high-risk neuroblastoma, to help immune system cells find and destroy the cancer cells.

Clinical trials are now testing the effectiveness of several other antibodies that target GD2:

Hu14.18-IL2 is an antibody that is linked to interleukin-2 (an immune-boosting cytokine). Early results have found that this antibody/cytokine combination may help some children for whom other treatments are no longer working.
Hu14.18K322A is a modified antibody that might work as well as other GD2 antibodies without some of the side effects.
Hu3F8 is another modified antibody that targets GD2. It is being studied in combination with other treatments.

Vaccines

Several cancer vaccines are also being studied for use against neuroblastoma. For these vaccines, injections of modified neuroblastoma cells or other substances are given to try to get the child’s own immune system to attack cancer cells. These treatments are still in the early stages of clinical trials.

CAR T-cell therapies

CAR T-cell therapy is a promising new way to get a patient's own immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. The T cells used in CAR T-cell therapies get changed in the lab to spot specific cancer cells by adding a man-made receptor (called a chimeric antigen receptor or CAR). One early trial created CAR T-cells to target GD2 on neuroblastoma cells. Other clinical trials are studying using CAR T-cells that target other proteins on the outside of neuroblastoma cells. These are very new clinical trials and are ongoing or in the planning phase. Talk to your doctor about these trials if you have questions.

Help fund this vital research

You can help fund groundbreaking research projects to find new, better treatments for children diagnosed neuroblastoma. Please donate today.

Please select a donation amount (required)
Set up a regular donationDonate

This information is reproduced with permission of The American Cancer Society from their page: What's New in Neuroblastoma Research.

The American Cancer Society medical and editorial content team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.

Last Medical Review: March 19, 2018 Last Revised: March 19, 2018

Published: 19th July, 2019

Updated: 11th March, 2022

Author:

Share this page
  • Email
  • Facebook
  • Twitter

Latest

  • September 2023

    September 2023

    FEATURED EVENT: Lumary City-Bay Fun Run in Adelaide is happening on Sunday 17 September 2023. Join our NBA team!

  • August 2023

    August 2023

    Be Part of the World's Largest Fun Run - City2Surf is back in 2023, aswell as Bridge to Brisbane this August.

  • July 2023

    July 2023

    More running events are happening in June including the Gold Coast Marathon and Run Melbourne! FInd out more here...

  • June 2023

    June 2023

    If you’re looking for something different for your next fitness challenge, look no further than Stadium Stomp Adelaide Oval - our featured event for June 2023.

Most read

  • Detection, diagnosis & staging

    Detection, diagnosis & staging

    Know about symptoms of neuroblastoma, detection, diagnosis and different stages of neuroblastoma childhood cancer.

  • What is neuroblastoma?

  • Emeline's Story

    Emeline's Story

    After months of misdiagnoses, including a middle-of-the-night emergency trip to the hospital, Emeline’s mum took her to a paediatric gastroenterologist believing her tummy issue was severe constipation. It turned out to be neuroblastoma.

  • Jazmyn's 2 many 2 young Walk

    Jazmyn's 2 many 2 young Walk

    Support this special 2.2 km walk - inspired by Jazmyn Mitchell. Dress Up and wear a tutu 2 help raise awareness on 18.02.2023 and support all the children affected by neuroblastoma. This is Jazmyn's walk and legacy - a special light in this world.

  • Run2Cure Local 2022

    Run2Cure Local 2022

    This September, Childhood Cancer Awareness Month join Run2Cure Local 2022. Run, get fit and fundraise at a location near you!

  • How common is neuroblastoma?

  • Donate today

    Donate today

    Help us beat the number one toddler cancer. Please donate today to support world class Australian research into developing better, safer treatments with the ultimate goal of finding a definitive cure for all children diagnosed with neuroblastoma.

  • How dangerous is neuroblastoma?

  • How is it diagnosed?

  • Why does this cancer form?

Tag cloud

#GivingTuesdayNow #run2curelocal 2little 44kmfor44kids A gift for a child with cancer Donate today Golf2Cure research Zach's neuroblastoma story

Some of our generous supporters include:

  


 

  


Approved by:

 Social Impact 2020 Rating

  • Contact us
  • Media
  • Sitemap
  • Accessibility
  • Terms & Conditions
  • Privacy Policy

Registered charity ABN : 74 173 375 414
Neuroblastoma Australia Level 1, 441 Pacific Highway, Crows Nest, NSW 2065,
+61 (0)2 9906 2066, [email protected]